Overview of the European Regulatory Experience in the Review of Clinical Studies with Antibody Drug Conjugate (ADC) Products

Time: 9:20 am
day: Day One


  • Highlighting salient features of clinical development programmes
  • Summary of important issues and how these were addressed
  • Key learnings and some reflections for future development programmes